172 related articles for article (PubMed ID: 33917598)
1. Combining Magnetic Resonance Imaging with Systemic Monocyte Evaluation for the Implementation of GBM Management.
Giordano C; Sabatino G; Romano S; Della Pepa GM; Tufano M; D'Alessandris QG; Cottonaro S; Gessi M; Balducci M; Romano MF; Olivi A; Gaudino S; Colosimo C
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33917598
[TBL] [Abstract][Full Text] [Related]
2. The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma.
Giordano C; Marrone L; Romano S; Della Pepa GM; Donzelli CM; Tufano M; Capasso M; Lasorsa VA; Quintavalle C; Guerri G; Martucci M; Auricchio A; Gessi M; Sala E; Olivi A; Romano MF; Gaudino S
Cancer Res Commun; 2024 May; 4(5):1296-1306. PubMed ID: 38651817
[TBL] [Abstract][Full Text] [Related]
3. Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163.
Lapuc I; Bolkun L; Eljaszewicz A; Rusak M; Luksza E; Singh P; Miklasz P; Piszcz J; Ptaszynska-Kopczynska K; Jasiewicz M; Kaminski K; Dabrowska M; Bodzenta-Lukaszyk A; Kloczko J; Moniuszko M
Oncol Rep; 2015 Sep; 34(3):1269-78. PubMed ID: 26135617
[TBL] [Abstract][Full Text] [Related]
4. Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients.
Troiani T; Giunta EF; Tufano M; Vigorito V; Arrigo P; Argenziano G; Ciardiello F; Romano MF; Romano S
Br J Cancer; 2020 Jun; 122(12):1782-1790. PubMed ID: 32317723
[TBL] [Abstract][Full Text] [Related]
5. Increased circulating M2-like monocytes in patients with breast cancer.
Zhang B; Cao M; He Y; Liu Y; Zhang G; Yang C; Du Y; Xu J; Hu J; Gao F
Tumour Biol; 2017 Jun; 39(6):1010428317711571. PubMed ID: 28639912
[TBL] [Abstract][Full Text] [Related]
6. Comparative assessment of the recognition of domain-specific CD163 monoclonal antibodies in human monocytes explains wide discrepancy in reported levels of cellular surface CD163 expression.
Maniecki MB; Etzerodt A; Moestrup SK; Møller HJ; Graversen JH
Immunobiology; 2011 Aug; 216(8):882-90. PubMed ID: 21458881
[TBL] [Abstract][Full Text] [Related]
7. Hemoglobin induces monocyte recruitment and CD163-macrophage polarization in abdominal aortic aneurysm.
Rubio-Navarro A; Amaro Villalobos JM; Lindholt JS; Buendía I; Egido J; Blanco-Colio LM; Samaniego R; Meilhac O; Michel JB; Martín-Ventura JL; Moreno JA
Int J Cardiol; 2015 Dec; 201():66-78. PubMed ID: 26296046
[TBL] [Abstract][Full Text] [Related]
8. CD163 as a Biomarker in Colorectal Cancer: The Expression on Circulating Monocytes and Tumor-Associated Macrophages, and the Soluble Form in the Blood.
Krijgsman D; De Vries NL; Andersen MN; Skovbo A; Tollenaar RAEM; Møller HJ; Hokland M; Kuppen PJK
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824692
[TBL] [Abstract][Full Text] [Related]
9. CD163 levels, pro- and anti-inflammatory cytokine secretion of monocytes in children with pulmonary tuberculosis.
Aktas Cetin E; Pur Ozyigit L; Gelmez YM; Cakir E; Gedik AH; Deniz G
Pediatr Pulmonol; 2017 May; 52(5):675-683. PubMed ID: 27685837
[TBL] [Abstract][Full Text] [Related]
10. Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels.
Davis BH; Zarev PV
Cytometry B Clin Cytom; 2005 Jan; 63(1):16-22. PubMed ID: 15624200
[TBL] [Abstract][Full Text] [Related]
11. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
[TBL] [Abstract][Full Text] [Related]
12. CD163 as a Potential Biomarker of Monocyte Activation in Ischemic Stroke Patients.
Greco R; Demartini C; Zanaboni AM; Tumelero E; Persico A; Candeloro E; Morotti A; Amantea D; Tassorelli C
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201498
[TBL] [Abstract][Full Text] [Related]
13. Circulating CD14
Hou J; Zhang M; Ding Y; Wang X; Li T; Gao P; Jiang Y
Mediators Inflamm; 2018; 2018():5270657. PubMed ID: 30034290
[TBL] [Abstract][Full Text] [Related]
14. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.
Jones K; Vari F; Keane C; Crooks P; Nourse JP; Seymour LA; Gottlieb D; Ritchie D; Gill D; Gandhi MK
Clin Cancer Res; 2013 Feb; 19(3):731-42. PubMed ID: 23224400
[TBL] [Abstract][Full Text] [Related]
15. Differential expression and predictive value of monocyte scavenger receptor CD163 in populations with different tuberculosis infection statuses.
Liu Q; Ou Q; Chen H; Gao Y; Liu Y; Xu Y; Ruan Q; Zhang W; Shao L
BMC Infect Dis; 2019 Nov; 19(1):1006. PubMed ID: 31779590
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic commitment of monocytes towards a protective hemoglobin scavenging phenotype (CD14(pos)CD163(high)HLA-DR(low))following cardiopulmonary bypass.
Quimby KR; Greenidge A; Harris A; Landis RC
Cytometry B Clin Cytom; 2010 Sep; 78(5):357-60. PubMed ID: 20533393
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Expression Fluctuates Concurrently with Cyclin D in Glioblastoma Cells.
Tufano M; D'Arrigo P; D'Agostino M; Giordano C; Marrone L; Cesaro E; Romano MF; Romano S
Cells; 2021 Sep; 10(9):. PubMed ID: 34572014
[TBL] [Abstract][Full Text] [Related]
18. Monocyte isolation techniques significantly impact the phenotype of both isolated monocytes and derived macrophages in vitro.
Nielsen MC; Andersen MN; Møller HJ
Immunology; 2020 Jan; 159(1):63-74. PubMed ID: 31573680
[TBL] [Abstract][Full Text] [Related]
19. Different phenotypes of monocytes in patients with new-onset mild acute pancreatitis.
Zhang ML; Jiang YF; Wang XR; Ding LL; Wang HJ; Meng QQ; Gao PJ
World J Gastroenterol; 2017 Feb; 23(8):1477-1488. PubMed ID: 28293095
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
